GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — bo...
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
Author: Endpoints News
Read Original Article